{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:44:08Z","timestamp":1790534648511,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.purol.2022.04.007","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T23:04:39Z","timestamp":1653606279000},"page":"623-634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Avanc\u00e9es r\u00e9centes dans la prise en charge du cancer de la prostate localis\u00e9 \u00e0 haut risque\u00a0: mise au point par le Comit\u00e9 Prostate de l\u2019Association fran\u00e7aise d\u2019urologie"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6935-3873","authenticated-orcid":false,"given":"M.","family":"Baboudjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-B.","family":"Beauval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-5318","authenticated-orcid":false,"given":"G.","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-9366","authenticated-orcid":false,"given":"M.","family":"Gauth\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-3459","authenticated-orcid":false,"given":"A.","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"G.","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.purol.2022.04.007_bib0200","doi-asserted-by":"crossref","first-page":"e222246","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.purol.2022.04.007_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2020.12.004","article-title":"Stage and grade migration in prostate cancer treated with radical prostatectomy in a large German multicenter cohort","volume":"19","author":"Boehm","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.purol.2022.04.007_bib0210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2012.08.001","article-title":"Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study","volume":"63","author":"Rider","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.04.007_bib0215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","article-title":"Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study","volume":"67","author":"Joniau","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.04.007_bib0220","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.ijrobp.2011.04.037","article-title":"Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease","volume":"81","author":"Stenmark","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.purol.2022.04.007_bib0225","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00345-021-03631-7","article-title":"The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies","volume":"39","author":"Manceau","year":"2021","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.04.007_bib0230","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.04.007_bib0235","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/bju.14353","article-title":"Development and internal validation of a side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer","volume":"122","author":"Martini","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.04.007_bib0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.12.028","article-title":"Development and external validation of a novel nomogram to predict side-specific extraprostatic extension in patients with prostate cancer undergoing radical prostatectomy","author":"Soeterik","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.04.007_bib0245","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JU.0000000000002205","article-title":"An algorithm to personalize nerve sparing in men with unilateral high-risk prostate cancer","volume":"207","author":"Martini","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.04.007_bib0250","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"Anovel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"issue":"10231","key":"10.1016\/j.purol.2022.04.007_bib0255","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.purol.2022.04.007_bib0260","doi-asserted-by":"crossref","first-page":"737989","DOI":"10.3389\/fonc.2021.737989","article-title":"Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and multiparametric MRI for pelvic lymph node staging prior to radical prostatectomy in patients with intermediate to high-risk prostate cancer: a meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.purol.2022.04.007_bib0265","first-page":"1","author":"Stabile","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.04.007_bib0270","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.04.007_bib0275","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"10260","key":"10.1016\/j.purol.2022.04.007_bib0280","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.purol.2022.04.007_bib0285","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.purol.2022.04.007_bib0290","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2010.33.2999","article-title":"Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment","volume":"29","author":"Tzelepi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.04.007_bib0295","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","article-title":"Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.04.007_bib0300","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"11","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_suppl.","key":"10.1016\/j.purol.2022.04.007_bib0305","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1200\/JCO.2020.38.15_suppl.5504","article-title":"Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC)","volume":"38","author":"Efstathiou","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.04.007_bib0310","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000001702","article-title":"Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer","volume":"206","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.04.007_bib0315","article-title":"NEAR trial: a single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer","author":"Lee","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"26","key":"10.1016\/j.purol.2022.04.007_bib0320","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.04.007_bib0325","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.eururo.2018.01.012","article-title":"Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 Scandinavian Prostate Cancer Group 12 Trial","volume":"73","author":"Ahlgren","year":"2018","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.purol.2022.04.007_bib0330","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2017.76.4126","article-title":"Phase III intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high-risk prostate cancer after radical prostatectomy: SWOG S9921","volume":"36","author":"Hussain","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.04.007_bib0335","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/cancers13040759","article-title":"Stereotactic body radiotherapy for high-risk prostate cancer: a systematic review","volume":"13","author":"Foerster","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.purol.2022.04.007_bib0340","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"issue":"7","key":"10.1016\/j.purol.2022.04.007_bib0345","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.purol.2022.04.007_bib0350","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.04.007_bib0355","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.20.02438","article-title":"Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis","volume":"39","author":"Spratt","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2022.04.007_bib0360","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.04.007_bib0365","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2019.11.415","article-title":"Radiation dose escalation or longer androgen suppression to prevent distant progression in men with locally advanced prostate cancer: 10-year data from the TROG 03.04 RADAR Trial","volume":"106","author":"Joseph","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10323","key":"10.1016\/j.purol.2022.04.007_bib0370","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.purol.2022.04.007_bib0375","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 Trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2022.04.007_bib0380","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.purol.2022.04.007_bib0385","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.purol.2022.04.007_bib0195","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.21.00596","article-title":"Radiation and androgen deprivation therapy with or without docetaxel in the management of nonmetastatic unfavorable-risk prostate cancer: a prospective randomized trial","volume":"39","author":"D\u2019Amico","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670872200121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670872200121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:36:04Z","timestamp":1761114964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S116670872200121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S116670872200121X"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2022.04.007","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avanc\u00e9es r\u00e9centes dans la prise en charge du cancer de la prostate localis\u00e9 \u00e0 haut risque\u00a0: mise au point par le Comit\u00e9 Prostate de l\u2019Association fran\u00e7aise d\u2019urologie","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2022.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}